MAP2K1 and melanoma: The MEK1/2 inhibitors trametinib, binimetinib and cobimetinib have been approved for treatment of melanoma and BRAF-mutant non-small cell lung cancer, and several more MEK1/2 drugs are currently in clinical trials [95, 96].